|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Diagnosis and management of postural orthostatic tachycardia syndrome:A brief review显示文摘自从至少 1940,姿势的 orthostatic 心悸亢进症候群(壶) 被认出了。文学的评论在处理和结果为这个条件和宽变化在定义识别差别。这症候群看起来与不同 pathophysiology 描述一组条件,它要求定制到真位于 \O 下面混乱的处理。病人们需要充分被评估指导治疗。进一步的研究被要求有效地分类能生产这症候群的内在的 pathophysiology 的范围并且指导最佳的管理。 | Howraa Abed Patrick A Ball Le-Xin Wang | 2012 | Journal of Geriatric Cardiology2012，9，1： | 3 |
| 2 | Adherence to treatment guidelines in the pharmacological management of chronic heart failure in an Australian population显示文摘背景将记录长期的心失败(CHF ) 的 pharmacotherapy 并且在澳大利亚的人口评估坚持到治疗指南。方法 677 个病人的药理学管理(女性 46.7% , 75.5 +/- 11.6 年) 与 CHF 回顾地被分析。结果血管收缩素变换的使用酶(王牌) 禁止者 / 血管收缩素受体 blockers (ARB ) 和 -blockers 分别地是 58.2% 和 34.7% 。为王牌 inhibitors/ARBs 的弃权的主要原因是 hyperkalemia 并且提高了浆液 creatinine 水平。为没收到 -blockers, 的病人,气喘和长期的妨碍的肺的疾病是主要禁止徵候。在为王牌 inhibitors/ARBs 和 -blockers 的以上目标剂量的治疗为每药是低的(40.3% 和 28.9% ,分别地) 。为心失败的结论基于证据的医药治疗在下面在一张农村耐心的人口使用。进一步的研究被要求开发过程改进心失败药的最佳的使用。 | Dao-Kuo Yao Le-Xin Wang Shane Curran Patrick Ball | 2011 | Journal of Geriatric Cardiology2011，8，2： | 2 |
| 3 | The Novel Marker, DOG1 , Is Expressed Ubiquitously in Gastrointestinal Stromal Tumors Irrespective of KIT or PDGFRA Mutation Status显示文摘 | Robert B. West Christopher L. Corless Xin Chen Brian P. Rubin Subbaya Subramanian Kelli Montgomery Shirley Zhu Catherine A. Ball Torsten O. Nielsen Rajiv Patel John R. Goldblum Patrick O. Brown Michael C. Heinrich Matt van de Rijn | 2004 | The American Journal of Pathology2004，，1： | 1 |
| 4 | Oxidation of Roading Asphalts 显示文摘 | Herrington P R Patrick J E Ball G F A | 1994 | IndEngChemRes1994，33，11： | 1 |
| 5 | Use of Traceback Methods To Confirm the Source of a Multistate Escherichia coli O157:H7 Outbreak Due to In-Shell Hazelnuts显示文摘 | Miller Benjamin D Rigdon Carrie E Ball Jill Rounds Joshua M Klos Rachel F Brennan Brenda M Arends Katherine D Kennelly Patrick Hedberg Craig Smith Kirk E | 2012 | EN2012，，2： | 1 |
| 6 | The normal and abnormal scrotum in children:evaluation with color Doppler sonography显示文摘 | Atkinson GO Jr Patrick LE Ball JI Jr | 1992 | Am J Roentgenol1992，158，3： | 1 |
| 7 | The normal and abnormal scrotum in children: evaluation with color Doppler sonography显示文摘 | Atkinson GO Jr Patrick LE Ball TI Jr | 1992 | AJR Am J Roentgenol1992，158，3： | 1 |
| 8 | Pediatric blunt abdom- inal trauma: peripoctal tracking at CT 显示文摘 | Patrick LE Ball Ti Atkinson GO | 1992 | Radiology1992，183，6： | 1 |
| 9 | Oxidation of roading asphalts显示文摘 | Herrington P R Patrick J E Ball G F A | 1994 | Industrial & Engineering Chemistry Research1994，33，11： | 1 |
| 10 | Oxidation of Roading Asphalts显示文摘 | HERRINGTON P R PATRICK J E BALL G F A | 1994 | Industrial & Engineering Chemistry Research1994，33，11： | 1 |
| 11 | The normaland abnormal scrotum in children: evaluation with colorDoppler sonography 显示文摘 | Atkinson GO Jr Patrick LE Ball TI Jr | 1992 | Am J Roentgenol1992，158，3： | 1 |
| 12 | Pediatric blunt abdominal trauma : periportal tracking at CT 显示文摘 | Patrick LE Ball TI Atkinson GO | 1992 | Radiology1992，183，68： | 1 |
| 13 | Melanotic neuroectodermal tumor of infancy显示文摘 | G. O. Atkinson M.D. P. C. Davis L. E. Patrick K. J. Winn T. I. Ball J. B. Wyly | 1989 | Pediatric Radiology (-)1989，，1： | 1 |
| 14 | The Novel Marker, DOG1 , Is Expressed Ubiquitously in Gastrointestinal Stromal Tumors Irrespective of KIT or PDGFRA Mutation Status显示文摘 | Robert B. West Christopher L. Corless Xin Chen Brian P. Rubin Subbaya Subramanian Kelli Montgomery Shirley Zhu Catherine A. Ball Torsten O. Nielsen Rajiv Patel John R. Goldblum Patrick O. Brown Michael C. Heinrich Matt van de Rijn | 2004 | The American Journal of Pathology2004，，1： | 1 |
| 15 | Pancreaticoenteric Fistula: No Longer a Surgical Disease?显示文摘 | Herbert C. Wolfsen Richard A. Kozarek Terrence J. Ball David J. Patterson L. William Traverso Patrick C. Freeny | 1992 | Journal of Clinical Gastroenterology1992，，2： | 1 |
| 16 | The normal and abnormal scrotum in children: evaluation with color Doppler sonography 显示文摘 | Atkinson GO Patrick LE Ball TI Jr | 1992 | AJR1992，158，： | 1 |
| 17 | Imaging findings ofperforative appendicitis:a pictorial review显示文摘 | Hopkins KA Patrick LE Ball TI | 2001 | Pediatr Radiol2001，31，： | 1 |
| 18 | The Juvenile Diabetes Research Foundation Network for Pancreatic Organ Donors with Diabetes ( nPOD ) Program: goals, operational model and emerging findings显示文摘 | Alberto Pugliese Mingder Yang Irina Kusmarteva Tiffany Heiple Francesco Vendrame Clive Wasserfall Patrick Rowe Jayne M Moraski Suzanne Ball Les Jebson Desmond A Schatz Roberto Gianani George W Burke Concepcion Nierras Teo Staeva John S Kaddis Martha Campb | 2014 | Pediatr Diabetes2014，，1： | 1 |
| 19 | Safety and immunogenicity of a third dose of mRNA-1273 vaccine among cancer patients显示文摘Background:Compared to the general population,cancer patients are at higher risk of morbidity and mortality following SARS-CoV-2 infection.The immune response to a two-dose regimen ofmRNA vaccines in cancer patients is generally lower than in immunocompetent individuals.Booster doses may meaningfully augment immune response in this population.We conducted an observational study with the primary objective of determining the immunogenicity of vaccine dose three(100μg)of mRNA-1273 among cancer patients and a secondary objective of evaluating safety at 14 and 28 days.Methods:The mRNA-1273 vaccine was administered~7 to 9 months after administering two vaccine doses(i.e.,the primary series).Immune responses(enzyme-linked immunosorbent assay[ELISA])were assessed 28 days post-dose three.Adverse events were collected at days 14(±5)and 28(+5)post-dose three.Fisher exact or X^(2)tests were used to compare SARS-CoV-2 antibody positivity rates,and paired t-tests were used to compare SARS-CoV-2 antibody geometric mean titers(GMTs)across different time intervals.Results:Among 284 adults diagnosed with solid tumors or hematologic malignancies,dose three of mRNA-1273 increased the percentage of patients seropositive for SARS-CoV-2 antibody from 81.7%pre-dose three to 94.4%28 days post-dose three.GMTs increased 19.0-fold(15.8-22.8).Patients with lymphoid cancers or solid tumors had the lowest and highest antibody titers post-dose three,respectively.Antibody responses after dose three were reduced among those who received anti-CD20 antibody treatment,had lower total lymphocyte counts and received anticancer therapy within 3 months.Among patients seronegative for SARS-CoV-2 antibody pre-dose three,69.2%seroconverted after dose three.A majority(70.4%)experienced mostly mild,transient adverse reactions within 14 days of dose three,whereas severe treatment-emergent events within 28 days were very rare(<2%).Conclusion:Dose three of the mRNA-1273 vaccine was well-tolerated and augmented SARS-CoV-2 seropositivity in cancer patients,especially those who did not seroconvert post-dose two or whose GMTs significantly waned post-dose two.Lymphoid cancer patients experienced lower humoral responses to dose three of the mRNA-1273 vaccine,suggesting that timely access to boosters is important for this population. | Anna Giuliano Barbara Kuter Shari Pilon-Thomas Junmin Whiting Qianxing Mo Brett Leav Bradley Sirak Christopher Cubitt Christopher Dukes Kimberly Isaacs-Soriano Kayoko Kennedy Somedeb Ball Ning Dong Akriti Jain Patrick Hwu Jeffrey Lancet | 2023 | Cancer Communications2023，43，7： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员